To evaluate the safety and effectiveness of the SAPIEN XT (Edwards Lifesciences, Irvine, California) transcatheter heart valve implantation (TAVI) in Chinese patients with symptomatic severe calcific aortic stenosis who are considered at high risk for surgical valve replacement.
Edwards SAPIEN XT™ Transcatheter Heart Valve and NovaFlex+ delivery system will be used for this study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
67
Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
WestChina Hospital, Sichuan University
Sichuan, Chengdu, China
Fuwai Hospital, CAMS&PUMC
Beijing, China
The Second Affiliated Hospital of Zhejiang University School of
Hangzhou, China
All-cause Mortality
All of the deaths that occurred in this population regardless of the cause.
Time frame: 30 days
Cardiovascular Mortality
All of the deaths that occurred in this population due to a cardiovascular issue.
Time frame: 30 days
Number of Participates With a Stroke
Total number of participates with a stroke.
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.